Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Gene expression profiling of gastric mucosa in mice lacking CCK and gastrin receptors

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Natriuretic peptides and cerebral hemodynamics

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Adropin: a new regulatory peptide in cardiovascular endocrinology

    Research output: Contribution to journalJournal articleResearch

  4. Cardiac C-type natriuretic peptide gene expression and plasma concentrations in neonatal piglets

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Gut hormones - Team workers or solo trippers?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Genetic Determinants of Weight Loss After Bariatric Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Pros and cons of Roux en-Y gastric bypass surgery in obese patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
The incretin hormone, glucose-dependent insulinotropic polypeptide (GIP, previously known as gastric inhibitory polypeptide), is rapidly degraded to the biologically inactive metabolite GIP (3-42) in the circulation, but little is known about the kinetics of the intact hormone and the metabolite and whether differences exist between patients with type 2 diabetes mellitus and healthy subjects. We examined eight type 2 diabetic patients (six men, two women); mean (range) age: 59 (48-69) years; BMI: 31.6 (26.0-37.7) kg/m2; HbA1C: 9.0 (8.2-13.2) %; fasting plasma glucose (FPG): 10.0 (8.3-13.2) mmol/l and 8 healthy subjects matched for age, gender and BMI. An intravenous bolus injection of GIP (7.5 nmol) was given and venous blood samples were drawn the following 45 minutes. Peak concentrations of total GIP (intact+metabolite, mean+/-SEM) and intact GIP (in brackets) were 920+/-91 (442+/-52) pmol/l in the type 2 diabetic patients and 775+/-68 (424+/-30) pmol/l in the healthy subjects (NS). GIP was eliminated rapidly with the clearance rate for intact GIP being 2.3+/-0.2 l/min in the type 2 diabetic patients and 2.4+/-0.2 l/min in the healthy subjects (NS). The volumes of distributions were similar in the two groups and ranged from 8 to 21 l per subject. The primary metabolite, GIP 3-42, generated through the action of dipeptidyl peptidase IV (DPP-IV), was eliminated with a mean half-life of 17.5 and 20.5 min in patients and healthy subjects (NS). CONCLUSION: Elimination of GIP is similar in obese type 2 diabetic patients and matched healthy subjects. Differences in elimination of GIP and its primary metabolite, therefore, do not seem to contribute to the defective insulinotropic effect of GIP in type 2 diabetes.
Original languageEnglish
JournalRegulatory Peptides
Volume137
Issue number3
Pages (from-to)168-72
Number of pages5
ISSN0167-0115
DOIs
Publication statusPublished - 10 Dec 2006

ID: 32268289